Management of dyslipidemia in adult solid organ transplant recipients

Bruce A. Warden, Paul Duell

Research output: Contribution to journalReview article

6 Scopus citations

Abstract

Solid organ transplantation (SOT) has revolutionized treatment of end-stage disease. Improvements in the SOT continuum of care have unmasked a significant burden of cardiovascular disease, manifesting as a leading cause of morbidity and mortality. Although several risk factors for development of post-transplant cardiovascular disease exist, dyslipidemia remains one of the most frequent and modifiable risks. An important contributor to dyslipidemia in SOT recipients is the off-target metabolic effects of immunosuppressive medications, which may alter lipoproteins and their metabolism. Dyslipidemia management is paramount as lipid-lowering therapy with statins has demonstrated reductions in graft vasculopathy, decreased rejection rates, and improved survival. Several nonstatin medication options are available, but data supporting their benefit in the SOT population are minimal, typically extrapolated from studies in the general population. Further compounding dyslipidemia management is the complex interplay of drug interactions between lipid-lowering and immunosuppressant medications, which can result in serious toxicity and/or therapeutic failure.

Original languageEnglish (US)
JournalJournal of clinical lipidology
DOIs
StatePublished - Jan 1 2019

Keywords

  • Drug-drug interactions
  • Dyslipidemia
  • Immunosuppression
  • Lipid-lowering therapy
  • Solid organ transplantation

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Management of dyslipidemia in adult solid organ transplant recipients'. Together they form a unique fingerprint.

  • Cite this